Risk of cardiovascular events following intermittent and continuous androgen deprivation therapy in patients with nonmetastatic prostate cancer

By sjmartinez • July 14, 2024

Preston MA, Ebrahimi R, Hong A, Bobbili P, Desai R, Duh MS, Gandhi R, Hanson S, Dufour R, Morgans AK. Risk of cardiovascular events following intermittent and continuous androgen deprivation therapy in patients with nonmetastatic prostate cancer. Urol Oncol. 2024 Jul 12:S1078-1439(24)00499-X. doi: 10.1016/j.urolonc.2024.05.026. Epub ahead of print. PMID: 39003108.

Tags: Androgen deprivation therapy, Cardiology/Epi, cardiovascular risk, Continuous ADT, Endocrine or metabolic risk, Intermittent ADT, Nonmetastatic prostate cancer, Publications, Veterans Administration

Related Posts

FAP Expression in Renal Tumors Assessed by [68Ga]Ga-FAPI-46 PET Imaging and FAP Immunohistochemistry: A Case Series of Six Patients from the Prospective Exploratory Trial NCT04147494

Holzgreve A, Unterrainer LM, Flores K, Lam EC, Mona CE, Czernin J, Shuch BM, Sisk AE Jr, Calais J. FAP Expression in Renal Tumors Assessed[...]

Akebia Saponin D Targeting Ubiquitin Carboxyl-Terminal Hydrolase 4 Promotes Peroxisome Proliferator-Activated Receptor Gamma Deubiquitination and Activation of Brown Adipose Tissue Thermogenesis in Obesity

Chen L, Liu DH, Li YX, Yang S, Jia WH, Peng L, Liu HL, Wang XB, Hu B, Wang YC, Pan C, Lusis AJ, Liu[...]

The relationship between blood eosinophil count and cardiovascular outcomes in prediabetes and diabetes patients with acute coronary syndrome: insights from a large Asian cohort analysis

Feng X, Liu Y, Qin H, Zhao S, Yang J, Yang S, Zhou Z, Liu Y, Wang Z, Shi D, Zhou Y, Guo Q. The[...]